Is the full-year guidance raise primarily due to Q1 outperformance, and is the company taking a conservative approach for the rest of the year?

The majority of the guidance increase is indeed driven by the North American Pharmaceutical business performing at the high end of its operating profit range. The forecast is intended to be a balanced view, not a best-case scenario. Management expresses high confidence due to broad-based momentum across NAP, Oncology & Multispecialty, and Prescription Technology Solutions, all showing double-digit operating profit growth, and strong Q1 execution, with June being the strongest month. “We are pleased with the continued momentum in our business, and that is the reason why we guided $0.40 above the last midpoint. And you can see broad-based growth, right? NAP, as you mentioned, has definitely shown momentum, but it wasn't just NAP, it was O&M as well and RxTS, all grew double digits for the quarter.”

Could you provide more detail on the drivers of accelerated growth in the Oncology and Multispecialty segment, including Florida Cancer's performance?

The 33% revenue growth in Oncology and Multispecialty was driven by three factors: strong growth in existing provider solutions and specialty distribution, new business wins, and contributions from the Core Ventures acquisition (which accounted for approximately 9% of the growth, making organic growth around 24%). Operating profit grew 41% (approximately 50% ex-Core Ventures). Florida Cancer integration has been very successful, with solid operations and financial performance at the high end of expectations. “If you normalize for Core Ventures of the 33%, it's roughly 24%. And then on the AOP side, we grew 41% year-over-year. If you normalize for Core Ventures, it was roughly 50%, which is in line with the long-term targets.”

What is the impact of potential 340B changes on the North American business, and what other policy items (like IRA Part D) is the company watching?

Regarding 340B, changes are preliminary and under review, so it's premature to speculate on financial impact. McKesson serves diverse stakeholders and will help customers navigate changes, leveraging its scale, technology, and compliance expertise. For IRA Part D, it's not effective until January 2028, with many unknowns. The company believes the GLOBE program, where price reductions occur via manufacturer rebates to CMS without impacting provider practices, is a good model for protecting community-based care. WAC pricing changes impact revenue but not operating profit due to fee-for-service contracts. “We think it's going to be important to let that process play out before we draw any conclusions about the final structure or timing or anything... it'd be premature to speculate on the financial impact. But I feel very confident in the capabilities of McKesson in partnership with our customers that we can navigate that.”

MCK

McKesson (MCK) Q1 FY27 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q1 FY27)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

McKesson Q1 FY27 — Strong Performance Drives Raised Full-Year EPS Guidance

McKesson delivered a strong first quarter, with broad-based momentum across its segments, particularly in North American Pharmaceutical and Oncology and Multispecialty, leading to a raise in full-year adjusted EPS guidance. The company continues to execute on strategic priorities, including the separation of Medical-Surgical Solutions and investments in AI and infrastructure, while navigating dynamic policy environments like 340B and IRA Part D.

Highlights

Revenues increased 8% to $105.4 billion, exceeding expectations.
Adjusted earnings per diluted share increased 20% to $9.93, exceeding expectations.
Full-year adjusted EPS guidance raised to $44.20-$45.00, reflecting strong momentum.
North American Pharmaceutical segment operating profit increased 19%, driven by specialty distribution and new product launches.
Oncology and Multispecialty segment revenue grew 33% (24% ex-Core Ventures) and operating profit grew 41% (15% ex-Core Ventures).

Concerns

Operating profit in Medical-Surgical Solutions decreased 20% to $195 million, driven by product mix and one-time administrative expenses.
Negative free cash flow of $372 million in Q1 FY27, though an improvement from prior year.
Lower branded pharmaceutical pricing following WAC decreases in January 2026 partially offset revenue growth in North American Pharmaceutical.

Guidance & targets

Category	Target	Timeline	Confidence
Adjusted earnings per diluted share	$44.20 to $45.00 high materiality	Full-year FY27	High
Revenue growth	5% to 9% high materiality	Full-year FY27	High
Operating profit growth	9% to 13% high materiality	Full-year FY27	High
North American Pharmaceutical revenue growth	4% to 8% medium materiality	Full-year FY27	High
North American Pharmaceutical operating profit growth	high end of 5.5% to 9.5% medium materiality	Full-year FY27	High
Oncology and Multispecialty revenue growth	14.5% to 18.5% medium materiality	Full-year FY27	High
Oncology and Multispecialty operating profit growth	13.5% to 17.5% medium materiality	Full-year FY27	High
Prescription Technology Solutions revenue increase	2.5% to 6.5% medium materiality	Full-year FY27	High
Prescription Technology Solutions operating profit increase	11% to 15% medium materiality	Full-year FY27	High
Medical-Surgical Solutions revenue growth	1% to 6% medium materiality	Full-year FY27	High
Medical-Surgical Solutions operating profit growth	flat to 4% medium materiality	Full-year FY27	High
Corporate expenses	$580 million to $640 million low materiality	Full-year FY27	High
Interest expense	$380 million to $420 million low materiality	Full-year FY27	High
Income attributable to noncontrolling interest	$295 million to $325 million low materiality	Full-year FY27	High
Effective tax rate	18% to 19% low materiality	Full-year FY27	High
Free cash flow	$4.5 billion to $4.9 billion high materiality	Full-year FY27	High
Share repurchases	approximately $5 billion high materiality	Full-year FY27	High
Weighted average diluted shares outstanding	115.5 million to 117.5 million low materiality	Full-year FY27	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
North American Pharmaceuticals Driven by broad-based growth from higher prescription volumes, including an increase in specialty products. Partially offset by lower branded pharmaceutical pricing following WAC decreases in January 2026 and branded to generic conversions, which did not meaningfully impact operating profit. Fundamentals remain strong, supported by stable utilization trends, specialty growth, and the strength of the generic sourcing program.	$86.8 billion	5%	—	$894 million
Oncology and Multispecialty Revenues driven by growth across the platform, including organic and new business growth in provider solutions, and contributions from the Core Ventures acquisition (completed June 2, 2025). Excluding Core Ventures, revenues grew approximately 24% and operating profit grew approximately 15%. Growth supported by solid utilization trends in the community setting and stable same-store patient visit growth. U.S. Oncology Network providers: 3,400U.S. Oncology Network patients treated annually: 2 millionPRISM Vision providers: 200PRISM Vision locations: 97	$14.2 billion	33%	—	$405 million
Prescription Technology Solutions Revenues driven by higher prescription volumes in third-party logistics and access solutions. Operating profit driven by higher demand for access solutions, including prior authorization services. Strong demand across technology solutions with growth driven by both GLP-1 medications and other therapeutic categories. Prior authorization requests determined within 30 minutes: 95%	$1.6 billion	9%	—	$303 million
Medical-Surgical Solutions Improvement in revenue growth trends compared to prior quarters, driven by growth across alternate sites of care, led by higher volumes of specialty pharmaceuticals. Operating profit decreased due to product mix and one-time administrative expense, partially offset by contributions from the extended care channel. Minority ownership interest from Apollo Funds (approx. 13%) completed June 1.	$2.8 billion	4%	—	$195 million

MCK operating KPIs by quarter

MCK operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2024 Q3 FY25	Jun 2025 Q1 FY26	Sep 2025 Q2 FY26	Dec 2025 Q3 FY26	Mar 2026 Q4 FY26	This call Jun 2026 Q1 FY27	Change vs prior quarter
Providers US Oncology Network	2,750+ We're pleased to see the continued expansion growing to over 2,750 providers across 640 sites of care in 31 different states. Source: earnings call transcript	~3,300 This marks an important step forward in our efforts to expand access to exceptional cancer care in local communities, growing the footprint of the US Oncology Network to approximately 3,300 providers across 700 sites in 30 states. Source: earnings call transcript	3,300+ The US Oncology Network has been leading the cancer care transformation for more than 15 years and is now supporting over 3,300 providers across more than 700 sites across the country. Source: earnings call transcript	~3,400 Today, the US oncology network has approximately 3,400 providers, and PRISM Vision brings together over 200 providers in retina and ophthalmology. Source: earnings call transcript	—	~3,400 The US Oncology Network grew to approximately 3,400 providers and treats more than 2 million patients annually. Source: earnings call transcript	—
Sites of care US Oncology Network	640 We're pleased to see the continued expansion growing to over 2,750 providers across 640 sites of care in 31 different states. Source: earnings call transcript	700 This marks an important step forward in our efforts to expand access to exceptional cancer care in local communities, growing the footprint of the US Oncology Network to approximately 3,300 providers across 700 sites in 30 states. Source: earnings call transcript	700+ The US Oncology Network has been leading the cancer care transformation for more than 15 years and is now supporting over 3,300 providers across more than 700 sites across the country. Source: earnings call transcript	—	—	—	—
Employees	—	45K Everything we achieve is made possible by the dedication and the commitment of our 45,000 employees. Source: earnings call transcript	—	—	43K As we close out a really great fiscal '26, I want to thank the 43,000 McKesson employees for their commitment to the work they do every day to advance our mission. Source: earnings call transcript	—	—
Providers PRISM Vision	—	—	—	200+ Today, the US oncology network has approximately 3,400 providers, and PRISM Vision brings together over 200 providers in retina and ophthalmology. Source: earnings call transcript	—	200+ PRISM Vision brings together over 200 providers in 97 locations, helping expand access to high-quality retina and ophthalmology care, again, in the community setting. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Deals & partnerships

Apollo Funds Strategic minority investment in Medical-Surgical Solutions

Apollo Funds now holds approximately 13% minority ownership interest in MedSurg. Completed on June 1, 2025.

Pfizer Strategic oncology research collaboration to accelerate clinical trials

Through Sarah Cannon Research Institute (SCRI), leveraging a next-generation clinical trial delivery model to streamline operations, enhance site efficiency, and reduce administrative burden.

Risks & headwinds

Lower branded pharmaceutical pricing (WAC decreases) January 2026 (ongoing)

Impacted revenue in North American Pharmaceutical, but not meaningfully operating profit.

Mitigation:Fee-for-service contracts ensure minimal impact on operating profit; company manages through dynamics.

Product mix and one-time administrative expense in Medical-Surgical Solutions Q1 FY27

Operating profit decreased 20% to $195 million.

Mitigation:Focused on disciplined execution and operating efficiencies.

Dynamic policy environment (e.g., 340B changes, IRA Part D) Ongoing, 340B under review, IRA Part D effective Jan 2028.

Premature to speculate on financial impact for 340B. IRA Part D not until Jan 2028 with many unknowns.

Mitigation:McKesson is highly engaged, leveraging scale, technology, and compliance expertise to help customers navigate changes. Advocates for models like GLOBE that protect community providers.

Quarterly variability in Prescription Technology Solutions performance Quarter-to-quarter

Not quantified, but noted as 'not always linear'.

Mitigation:Driven by utilization trends, product launch timing, program support requirements. Visibility into opportunities and strength of existing programs support expectations.

Accelerated investments in North American Pharmaceutical Second half of fiscal '27

Not quantified, but noted as 'accelerated investments'.

Mitigation:Focused on growth and AI, with return on investment expected to be accretive to enterprise, likely beginning of FY28.

What to watch in Q2 FY27

North American Pharmaceutical Operating Profit Growth

H2 FY27

Current +19% in Q1 FY27

Target High end of 5.5-9.5% for FY27

Why it matters

Management noted Q1 benefited from early generic pops and accelerated investments in H2 FY27 could impact later quarters, making the sustained high-end performance important.

I would say, Michael, that we probably had some favorability in the generics portion of the business that came earlier in the year than we would have expected it to. That obviously will come at the expense of later quarters, we benefited early.

Find out whether MCK delivers this. Inve re-checks your case every morning.

Q&A highlights

What drove the strong organic growth and margin expansion in the North American Pharmaceutical segment, given the strong operating earnings growth relative to revenue?

The strong Q1 performance was driven by increased prescription transaction volume, including higher specialty product volume, and the timing of new product launches (both new branded and branded generics). Operating profit grew faster than revenue due to a higher margin mix from specialty distribution to health systems. Operating margin changes can be influenced by customer mix, product mix (specialty, generics, biosimilars), and channel.

“On the AOP, we increased 19% for the first quarter. It's really driven by the distribution of specialty products to the health system and timing of new product launches.”

asked by George Hill · answered by Kenny Cheung

2 min read 6 chapters

Detailed narrative

Strategic Priorities & AI Integration

McKesson is focused on developing talent and leveraging AI to drive measurable business outcomes. A full-day enterprise AI training was hosted at headquarters, bringing teams together for educational sessions and hands-on learning. This investment strengthens operations, innovation, and long-term value creation, with examples demonstrating the potential to scale AI capabilities more broadly across segments.

Oncology and Multi-Specialty Platform Growth

The company is capitalizing on specialty therapy growth, serving over 14,000 providers across community-based specialties. The U.S. Oncology Network grew to approximately 3,400 providers, treating over 2 million patients annually, while PRISM Vision expanded to over 200 providers in 97 locations. A strategic oncology research collaboration with Pfizer was announced to accelerate clinical trials, leveraging a next-generation delivery model.

Biopharma Services and GLP-1 Support

McKesson enables connectivity across providers, biopharma, pharmacies, and payers, advancing access and affordability programs. The company began supporting the CMS Medicare GLP-1 Bridge program in July, facilitating eligibility determination, electronic prior authorization, and pharmacy claims. New program wins demonstrate broad demand for their technology-driven solutions across various therapeutic categories, improving patient access to therapy.

North American Distribution & Infrastructure

The core distribution business delivered strong growth, supported by stable fundamentals and diversified channel reach. McKesson broke ground on a new regional distribution center in Moore, Oklahoma, representing an important investment to strengthen supply chain resiliency. This facility will increase throughput by 75% compared to the prior facility, supported by advanced automation, digitally enabled logistics, and expanded cold chain capabilities.

Medical-Surgical Solutions Separation (Wellverse)

The planned separation of Medical-Surgical Solutions is progressing, with the business now branded as Wellverse, anticipating formal operation starting January 2027. A strategic minority investment from Apollo Funds was completed, and a $2.25 billion senior secured Term Loan B was established, further building a stand-alone capital structure. These actions support financial flexibility and reinforce focus on maximizing long-term shareholder value.

Policy Environment Engagement

McKesson remains highly engaged in the dynamic policy environment, focusing on the important role of community-based care, access, cost, and transparency. The company became a signatory to technology pledges under the CMS Healthcare Technology Ecosystem initiative. As a diversified health care services company, it aims to strengthen the pharmaceutical supply chain, improve access and affordability, and enable innovation for better patient outcomes.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.